A new drug is currently being tested in a U.S. trial led in part by George Mason University, SciTechDaily reports.
The study includes individuals who previously lost weight using weight-loss medication but have since discontinued treatment.
Researchers are examining how much weight participants regain and comparing it with existing knowledge about weight gain after discontinuation.
Participants are aware that they are receiving the medication, and there is no control group.
Also read: Stopping GLP-1 drugs may reverse heart benefits, study finds
Controls appetite
The new drug, ARD-201, works differently from well-known injections. Instead of producing significant weight loss, it is intended to help regulate appetite.
According to George Mason University, the compound activates certain receptors in the body that normally respond to bitter taste.
Even though no bitter taste is perceived, the body sends signals that may lead to reduced food intake.
Previous trials with a similar compound have shown that this mechanism can affect appetite in people with a rare condition characterized by constant hunger.
Also read: Trump’s hair draws attention – a familiar sign of aging
The challenge after weight loss
Medications such as Ozempic and Wegovy have made it easier for many people to lose weight.
However, many experience weight regain after stopping treatment, according to George Mason University.
The new trial aims to address this specific issue. The goal is not to induce further weight loss, but to help people maintain a stable weight.
Only when the trial results are available will it be possible to determine whether the drug can help sustain weight loss over the long term.
Also read: How beets can affect your kidneys if you eat them often
Sources: SciTechDaily.
Also read: Have you had a urinary tract infection? It may increase your risk of dementia
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.